Charlotte Safrit, a 47-year-old from Allentown, Pennsylvania, began experiencing unexpected hot flashes and sweating at the age of 42. These symptoms started after she underwent a double mastectomy, chemotherapy, and radiation treatment for triple-positive breast cancer. After discussing her symptoms with her oncologist, Safrit realized that the episodes of intense sweating were, in fact, hot flashes, a common symptom of menopause.
Safrit’s experience highlights a significant challenge for many cancer survivors—early menopause. As part of her cancer treatment, she had been prescribed medications to suppress estrogen, a hormone linked to cancer recurrence. Soon after, she began to experience other classic menopause symptoms, including night sweats, brain fog, joint pain, and even weight gain. These symptoms are also common among women undergoing natural menopause, which typically begins between ages 45 and 55, but can be triggered early in cancer survivors due to treatments like chemotherapy.
The Impact of Cancer Treatments on Menopause
For many women, the onset of menopause due to cancer treatments can be sudden and overwhelming. The typical menopause symptoms—hot flashes, night sweats, vaginal dryness, and more—can have a profound impact on daily life, affecting sleep, mood, cognition, and even sexual health. While hormone therapy is often an effective way to manage these symptoms, it is not recommended for women who have had hormone-sensitive cancers like breast cancer, leaving them with limited treatment options.
The Role of Elinzanetant: A Nonhormonal Treatment Option
In response to this gap in care, the U.S. Food and Drug Administration (FDA) recently approved a new nonhormonal drug called elinzanetant (brand name Lynkuet). This drug offers hope for cancer survivors and other women who cannot use hormone therapies. Elinzanetant works by targeting specific receptors in the brain that regulate temperature, blocking the body’s overreaction to temperature changes without affecting hormone levels.
Lynkuet is expected to be available to patients in the coming months, providing a new and exciting option for managing menopause symptoms without the use of hormones. The medication offers a targeted approach to reducing hot flashes and night sweats, common complaints among women going through menopause.
Medical Experts Respond to the New Treatment
Doctors in the Philadelphia region, including OB-GYN Dr. Elizabeth Clement from Penn Medicine, have praised the new drug as a significant step forward in women’s health. Dr. Clement emphasized the importance of the approval, noting that historically, nonhormonal options for menopause have been limited. She sees this development as a sign of increasing investment in women’s health, which has often been neglected in the past.
Other health professionals, such as OB-GYN Dr. Julia Switzer from Thomas Jefferson University, also see elinzanetant’s approval as a positive development. Dr. Switzer believes the new drug expands the “toolbox” for physicians, allowing them to offer effective treatments to a wider range of patients, including those with cancer histories or other health concerns that prevent the use of hormone therapies.
A Personal Advocate for Cancer Survivors: Safrit’s Journey
For cancer survivors like Safrit, the introduction of Lynkuet brings hope and empowerment. Safrit, who now runs a breast cancer support group in the Lehigh Valley, has become an advocate for raising awareness about the long-term effects of cancer treatment, including menopause. She encourages open conversations about menopause, which she feels are often stigmatized or avoided. By sharing her own experiences, Safrit helps other women feel comfortable discussing their symptoms and seeking treatment options.
Conclusion
The approval of Lynkuet marks a significant moment in the journey toward better menopause care, particularly for cancer survivors who face unique challenges. As medical professionals and patients alike continue to advocate for more treatment options, the availability of nonhormonal drugs like elinzanetant represents a hopeful step toward improving the quality of life for women experiencing menopause after cancer treatment.
Related topics
